Login to Your Account

ThromboGenics Stock Sky High on Microplasmin Phase III Data

By Cormac Sheridan

Wednesday, April 21, 2010
Shares in ThromboGenics NV reached an all-time during early trading Tuesday on news that its lead drug candidate, microplasmin, reached the primary endpoint in the first of two Phase III trials in the treatment of symptomatic focal vitreomacular adhesion (VMA). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription